This is a two phase study investigating combinations of pharmacological and behavioral interventions to optimize the treatment of Opioid Use Disorder (OUD). The Retention Phase will assess strategies for improving retention on buprenorphine (BUP) and extended-release injectable naltrexone (XR-NTX). The Discontinuation Phase will assess which approaches are most likely to lead to long-term success (absence of relapse), and what characteristics of participants distinguish those who can safely discontinue Medications for Opioid Use Disorder (MOUD) from those who remain at risk of relapse and should not discontinue.
Opioid Use Disorder (OUD)
This is a two phase study investigating combinations of pharmacological and behavioral interventions to optimize the treatment of Opioid Use Disorder (OUD). The Retention Phase will assess strategies for improving retention on buprenorphine (BUP) and extended-release injectable naltrexone (XR-NTX). The Discontinuation Phase will assess which approaches are most likely to lead to long-term success (absence of relapse), and what characteristics of participants distinguish those who can safely discontinue Medications for Opioid Use Disorder (MOUD) from those who remain at risk of relapse and should not discontinue.
Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
-
University of Arkansas for Medical Sciences (UAMS) / Center for Addiction Services and Treatment (CAST), Little Rock, Arkansas, United States, 72205
Tarzana Treatment Centers, Inc., Tarzana, California, United States, 91356
Liberation Programs, Inc., Bridgeport, Connecticut, United States, 06610
Operation PAR, Clearwater, Florida, United States, 33760
Gateway Community Services, Jacksonville, Florida, United States, 32204
Aspire Health Partners, Orlando, Florida, United States, 32806
Mountain Manor / Maryland Treatment Centers, Baltimore, Maryland, United States, 21229
McLean Hospital, Belmont, Massachusetts, United States, 02478
Stanley Street Treatment and Resources, Inc., Fall River, Massachusetts, United States, 02720
Square Medical Group, LLC, Newton, Massachusetts, United States, 02458
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
NYU Langone Health,
Edward V Nunes, MD, PRINCIPAL_INVESTIGATOR, New York State Psychiatric Institute/Columbia University Irving Medical Center
John Rotrosen, MD, PRINCIPAL_INVESTIGATOR, NYU Grossman School of Medicine
Roger Weiss, MD, PRINCIPAL_INVESTIGATOR, Harvard Medical School/McLean Hospital
2026-12-30